Inventiva News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

08.09.21	Inventiva announces the initiation of its pivotal Phase III clinical trial evaluating lanifibranor in NASH (GlobeNewswire)
30.08.21	Inventiva announces participation at several investor conferences in September 2021 (GlobeNewswire)
02.08.21	Inventiva announces the implementation of an At-The-Market program in the United States (GlobeNewswire)
28.07.21	Inventiva Reports First-Half of 2021 Financial Information (GlobeNewswire)
15.06.21	Inventiva to participate at the SVB Leerink CybeRx Series: Liver Disease Day (GlobeNewswire)
09.06.21	Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2021 and during a KOL webcast event (GlobeNewswire)
25.05.21	Inventiva to participate at the Jefferies Virtual Healthcare Conference (GlobeNewswire)
12.05.21	Inventiva reports first quarter 2021 financial information and updates on the collaboration with AbbVie in auto-immune diseases (GlobeNewswire)
26.04.21	Inventiva to participate at the 7th Annual Truist Securities Life Sciences Summit (GlobeNewswire)
19.04.21	Appointment of Martine Zimmermann as Independent Director to Inventiva’s Board of Directors (GlobeNewswire)
04.03.21	2020 Full-Year Results: Major advances in NASH and significantly extended cash runway through successful IPO in the United States (GlobeNewswire)
25.02.21	Inventiva announces collaboration on non-invasive biomarkers to identify patients responding to lanifibranor with regards to NASH resolution and fibrosis improvemen (GlobeNewswire)
24.02.21	Inventiva to participate at several investor conferences in March 2021 (GlobeNewswire)
11.02.21	Full-Year 2020: Cash position and revenues (GlobeNewswire)
06.01.21	Inventiva annonce sa participation à la « 39th Annual J.P. Morgan Healthcare Conference » (GlobeNewswire)
05.01.21	Inventiva announces design of Phase III clinical trial with lanifibranor in NASH (GlobeNewswire)
07.12.20	Inventiva announces the publication in the Journal of Hepatology of new pre-clinical data showing the beneficial effects of lanifibranor on cirrhosis (GlobeNewswire)
24.11.20	Inventiva to participate at the Piper Sandler 32nd Annual Virtual Healthcare Conference (GlobeNewswire)
12.11.20	Q3 2020 Financial Information (GlobeNewswire)
10.11.20	Inventiva receives positive FDA feedback to advance its lead drug candidate lanifibranor into pivotal Phase III in NASH (GlobeNewswire)
09.11.20	Inventiva to participate at the Stifel Virtual Healthcare Conference 2020 and the 11th Jefferies Virtual Healthcare Conference (GlobeNewswire)
05.11.20	Inventiva announces the appointment of Dr. Michael Cooreman as Chief Medical Officer (GlobeNewswire)
02.11.20	Inventiva announces the publication of a scientific paper on the role of PPARs in the treatment of NASH in the medical journal Nature Review Gastroenterology & Hepatology (GlobeNewswire)
02.11.20	Inventiva announces the additional acceptance of two late-breaking abstracts at the AASLD The Liver Meeting Digital Experience™ 2020 (GlobeNewswire)
28.10.20	Inventiva to host a Key Opinion Leader webcast from the AASLD The Liver Meeting Digital Experience™ 2020 (GlobeNewswire)
19.10.20	Inventiva receives FDA Fast Track designation in MPS VI for its clinical-stage asset odiparci (GlobeNewswire)
12.10.20	Inventiva receives FDA Breakthrough Therapy designation for lead drug candidate lanifibranor in NASH (GlobeNewswire)
05.10.20	Inventiva selected to present the results of its NATIVE Phase IIb clinical trial with lanifibranor in NASH during a plenary session at The Liver Meeting Digital Experience™ 2020 (GlobeNewswire)
24.09.20	Inventiva to participate at several investor conferences in October 2020 (GlobeNewswire)
16.09.20	H1 2020 financial results and corporate business update (GlobeNewswire)
09.09.20	Inventiva to participate at several investor conferences in September 2020 (GlobeNewswire)
06.07.20	H1 2020 Financial Information (GlobeNewswire)
06.07.20	Inventiva announces the decision by the investigator to reduce the number of patients in the ongoing Phase II trial evaluating lanifibranor in type 2 diabetes patients (T2DM) with Non-Alcoholic Fatty (GlobeNewswire)
15.06.20	Inventiva’s lanifibranor meets the primary and key secondary endpoints in the Phase IIb NATIVE clinical trial in non-alcoholic steatohepatitis (NASH (GlobeNewswire)
02.06.20	Inventiva to participate at the Jefferies Virtual Healthcare Conference (GlobeNewswire)
25.05.20	Inventiva secures a new patent for lanifibranor in China expanding the protection of its lead product candidate (GlobeNewswire)
19.05.20	Inventiva secures €10.0 m non-dilutive loan facility guaranteed by the French State in the context of the COVID-19 pandemic (GlobeNewswire)
18.05.20	Inventiva’s latest research on odiparcil’s mechanism of action published in leading peer-reviewed scientific journal PLOS ONE (GlobeNewswire)
14.05.20	Q1 2020 Financial Information (GlobeNewswire)
21.04.20	Inventiva to provide an update on the NATIVE Phase IIb clinical trial in NASH during a Key Opinion Leader webcast (GlobeNewswire)
07.04.20	Inventiva provides a corporate business update in the context of the COVID-19 pandemic (GlobeNewswire)
17.03.20	Inventiva announces completion of patient visits for its Phase IIb clinical study with lanifibranor in NASH (GlobeNewswire)
10.03.20	2019 Full-Year Results: Significant progress in NASH, MPS VI and psoriasis, and extended cash runway (GlobeNewswire)
19.02.20	Inventiva to present at the Cowen and Company 40th Annual Health Care Conference (GlobeNewswire)
07.02.20	Inventiva completes a capital increase of €15 m subscribed by existing shareholders (GlobeNewswire)
05.02.20	Full-Year 2019: Cash position and revenues (GlobeNewswire)
03.02.20	Inventiva selected to present the positive results from its Phase IIa clinical study with odiparcil in MPS VI at the 16th Annual WORLDSymposiumTM (GlobeNewswire)
06.01.20	Inventiva admitted to the SRD “Long only” on the regulated market of Euronext Paris (GlobeNewswire)
18.12.19	Inventiva announces positive results from Phase IIa clinical study with odiparcil in mucopolysaccharidosis type VI (GlobeNewswire)
03.12.19	Inventiva receives a €3.5 m milestone payment from AbbVie (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

CieFinRichemont	137.35	1.40 %	K V
Sonova Hldg	297.30	1.29 %	K V
Logitech Intl	74.86	1.22 %	K V
Nestle	75.22	1.02 %	K V
Alcon	76.32	0.95 %	K V
UBS Group	28.17	-0.67 %	K V
Swiss Re	131.95	-0.68 %	K V
Geberit	533.80	-0.78 %	K V
Lonza Grp	541.40	-0.81 %	K V
Kuehne+Nagel Int	202.60	-1.65 %	K V

Nachrichten zu Inventiva SA act ord

Aktien Top/Flop

Meistgelesene Nachrichten